SCHEMBL17985674

SCHEMBL17985674

Cc1cc(NCCCO)nc(NC(=N)Nc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 2/20 0.39
LMNA P02545 4/20 0.39
HTT P42858 3/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 3/20 0.38
CDK1 P06493 1/20 0.38
SYK P43405 1/20 0.37
STK17B O94768 1/20 0.36
CAMK2D Q13557 1/20 0.36
DNM2 P50570 6/20 0.36
BCL6 P41182 1/20 0.36
KDM4E B2RXH2 1/20 0.35
PLA2G1B P04054 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18017324 0.93 ALDH1A1 (0.38) STK17ALMNAHTTALDH1A1TP53
SCHEMBL17985643 0.91 DNM2 (0.46) STK17ALMNAHTTALDH1A1TP53
SCHEMBL18037995 0.87 NPC1 (0.52) LMNAHTTALDH1A1SMN1; SMN2NPC1
SCHEMBL23258168 0.84 NPC1 (0.51) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL18017317 0.83 DNM2 (0.45) LMNAHTTALDH1A1TP53TSHR
SCHEMBL20799360 0.83 NPC1 (0.44) LMNAHTTALDH1A1SMN1; SMN2NPC1
SCHEMBL23258569 0.80 NPC1 (0.54) LMNAHTTALDH1A1SMN1; SMN2NPC1
SCHEMBL25858213 0.80 KMT2A (0.45) LMNAHTTALDH1A1TP53TSHR
SCHEMBL17985492 0.79 KMT2A (0.49) LMNAHTTALDH1A1SMN1; SMN2NPC1
SCHEMBL18038051 0.78 NPC1 (0.52) STK17ALMNAHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227333-B2 Inhibition of OLIG2 activity GLI2, ING2, GMFG STK17A 2615/4885LMNA 4459/4885HTT 2086/4885
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG STK17A 2615/4885LMNA 4459/4885HTT 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.